Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 19;28(3):1909-1920.
doi: 10.3390/curroncol28030177.

Synovial Sarcoma: A Clinical Review

Aaron M Gazendam  1 , Snezana Popovic  2 , Sohaib Munir  3 , Naveen Parasu  3 , David Wilson  1 , Michelle Ghert  1
Affiliations
Review

Synovial Sarcoma: A Clinical Review

Aaron M Gazendam et al. Curr Oncol. .

Abstract

Synovial sarcomas (SS) represent a unique subset of soft tissue sarcomas (STS) and account for 5-10% of all STS. Synovial sarcoma differs from other STS by the relatively young age at diagnosis and clinical presentation. Synovial sarcomas have unique genomic characteristics and are driven by a pathognomonic t(X;18) chromosomal translocation and subsequent formation of the SS18:SSX fusion oncogenes. Similar to other STS, diagnosis can be obtained from a combination of history, physical examination, magnetic resonance imaging, biopsy and subsequent pathology, immunohistochemistry and molecular analysis. Increasing size, age and tumor grade have been demonstrated to be negative predictive factors for both local disease recurrence and metastasis. Wide surgical excision remains the standard of care for definitive treatment with adjuvant radiation utilized for larger and deeper lesions. There remains controversy surrounding the role of chemotherapy in the treatment of SS and there appears to be survival benefit in certain populations. As the understanding of the molecular and immunologic characteristics of SS evolve, several potential systematic therapies have been proposed.

Keywords: clinical review; current concepts; soft tissue sarcoma; synovial sarcoma.

PubMed Disclaimer

Conflict of interest statement

One author (M.G.) declares personal fees from Wright Medical, personal fees from Amgen, grants from the Canadian Institutes of Health Research, grants from the Canadian Cancer Society, grants from Hamilton Academic Health Sciences, outside the submitted work. All other authors have no conflicts to declare.

Figures

Figure 1
Figure 1
AP (A) and lateral (B) radiographs of the right (R) knee and lower leg in a 31-year-old male demonstrate coarse calcifications within the soft tissues adjacent to the posteromedial tibial plateau, corresponding to a biopsy proven synovial sarcoma. No significant articular abnormality. Adjacent bony structures appear unremarkable.
Figure 2
Figure 2
Sagittal MR images in the same patient demonstrate a periarticular soft tissue mass situated posteromedial to the proximal tibia, in close relation to the pes anserine tendons. The mass demonstrates intermediate signal on T1 weighted images (A), and heterogeneously high signal on T2 weighted fat-saturated images (B). T1 weighted fat-saturated after gadolinium administration (C), demonstrates heterogeneously avid enhancement. Known areas of calcification are low signal on all sequences (arrow).
Figure 3
Figure 3
(A) Microscopic images showing biphasic tumor composed of spindle cell (S) and epithelioid (E) component; H&E ×100 and (B) occasional calcifications (arrow); H&E ×200). (C) Microscopic image showing poorly differentiated morphology (H&E ×400). (D) Immunohistochemistry demonstrating diffuse and strong nuclear staining for the transcriptional corepressor TLE1 (×200).
Figure 4
Figure 4
Molecular study using fluorescence in situ hybridization (FISH) break apart probe confirmed a diagnosis of synovial sarcoma detecting the SS18 gene arrangement (split red and green signal) (×200).
See this image and copyright information in PMC

References

    1. Toro J.R., Travis L.B., Wu H.J., Zhu K., Fletcher C.D.M., Devesa S.S. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases. Int. J. Cancer. 2006;119:2922–2930. doi: 10.1002/ijc.22239. - DOI - PubMed
    1. Mastrangelo G., Coindre J.-M., Ducimetière F., Tos A.P.D., Fadda E., Blay J.-Y., Buja A., Fedeli U., Cegolon L., Frasson A., et al. Incidence of soft tissue sarcoma and beyond. Cancer. 2012;118:5339–5348. doi: 10.1002/cncr.27555. - DOI - PubMed
    1. WHO . Soft Tissue and Bone Tumours. 5th ed. IARC Press; Lyon, France: 2020. Classification of Tumours Editorial.
    1. Sultan I., Rodriguez-Galindo C., Saab R., Yasir S., Casanova M., Ferrari A. Comparing children and adults with synovial sarcoma in the surveillance, epidemiology, and end results program, 1983 to 2005. Cancer. 2009;115:3537–3547. doi: 10.1002/cncr.24424. - DOI - PubMed
    1. Aytekin M.N., Öztürk R., Amer K., Yapar A. Epidemiology, incidence, and survival of synovial sarcoma subtypes: SEER database analysis. J. Orthop. Surg. 2020;28:2309499020936009. doi: 10.1177/2309499020936009. - DOI - PubMed

Substances